Investigation of a Customized Femoral Resurfacing Implant (Knee100)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01690689
Recruitment Status : Unknown
Verified February 2015 by Episurf Medical AB.
Recruitment status was:  Recruiting
First Posted : September 24, 2012
Last Update Posted : February 24, 2015
Information provided by (Responsible Party):
Episurf Medical AB

Brief Summary:
The purpose is to assess the safety profile and performance of a femoral resurfacing implant for localized chondral lesions.

Condition or disease Intervention/treatment Phase
Articular Cartilage Disorder Device: Implant surgery Not Applicable

Detailed Description:
The implant's safety profile will be assessed by incidence of any subject having any of the seven identified implant-related clinical undesirable side effects. This will be analyzed with a one-side exact binomial test on significance level 0.05, at 24 months post-operatively.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 26 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Investigation of a Customized Femoral Resurfacing Implant (Episealer® Knee Condyle Device) to Assess the Safety Profile and Performance for 2 Years Post-operatively
Study Start Date : December 2012
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : February 2018

Arm Intervention/treatment
Experimental: Surgery
Implant surgery
Device: Implant surgery

Primary Outcome Measures :
  1. Number of participants with Adverse Events [ Time Frame: 24 months ]
    The primary efficacy analysis in this study is to ascertain that the incidence of at least one subject having any of the seven identified clinical undesirable side effects is lower than 38 % (risk profile of the comparator) up to the 24 months analysis in the PP population. This will be analyzed with a one-side exact binomial test on significance level 0.05

Secondary Outcome Measures :
  1. Clinical performance [ Time Frame: 24 months ]
    Clinical performance, by questionnaires and knee ROM measurements.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   30 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female
  2. Age 30 ≤ 65 years
  3. Chondral defects of the femoral cartilage ICRS grade 3 (severely abnormal cartilage defects > 50% of the cartilage depth) or grade 4 (severely abnormal, through the cartilage depth) on medial or lateral femoral condyles
  4. Cartilage lesion area < 3.2 cm2 (diameter < 2 cm)
  5. Failed earlier conservative or surgical interventions such as lavage, abrasions, drilling or microfracture
  6. VAS-pain symptom >40 for more than 6 months
  7. The arthroscopic finding corresponds to the expected; size of cartilage lesion is correct and no other significant pathology (see CIP, "Intra-operative check-list", Appendix I)
  8. Capable of completing self-administered questionnaires
  9. Willing to comply with the follow-up requirements of the study
  10. Signed informed consent

Exclusion Criteria:

  1. BMI ≥ 35 kg/m2 (severe obesity)
  2. Instability or deficiency of soft tissues, vascular or muscular insufficiency
  3. Metabolic disorders which may impair bone formation
  4. Diabetes mellitus
  5. Smokers
  6. Diagnosis of a concomitant knee injury which the Investigator appreciates may interfere with study participation (i.e. may confound efficacy assessment or healing at the involved knee joint level)
  7. Irresolvable joint pain or loss-of-function with an undeterminable cause
  8. Diagnosis of a concomitant meniscal injury in involved knee that requires surgical intervention
  9. Loss of joint space on standing radiographs (≥ 1 on Ahlbäck-scale (0-5))
  10. Avascular necrosis
  11. Infections, systemic or local
  12. Known metal allergies
  13. History of inflammatory arthritis
  14. Pregnancy
  15. Pacemaker implant
  16. History of drug or substance abuse
  17. Systemic administration within 30 days prior to the study of any type of corticosteroid, antineoplastics, immune stimulating or immunosuppressive agents
  18. Participation in another clinical trial using an investigational new drug or device within 30 days of entrance into this study.
  19. Condition that may have an impact on the outcome of the investigation as judged by the Investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01690689

Contact: Anders Stålman, MD, PhD
Contact: Birgitta Larsson, PhD

Lund University Hospital, Department of Ortopedics Active, not recruiting
Lund, Sweden
Vrinnevisjukhuset Recruiting
Norrköping, Sweden
Contact: Peter Rockborn, MD, PhD         
Aleris Specialistvård Recruiting
Stockholm, Sweden
Contact: Anders Stålman, MD, PhD    +46 (8)-690 63 15      
Principal Investigator: Anders Stålman, MD, PhD         
Sports Medicine Umeå Recruiting
Umeå, Sweden
Contact: Magnus Högström, MD, PhD         
Sponsors and Collaborators
Episurf Medical AB
Study Director: Nina Bake Episurf Medical

Responsible Party: Episurf Medical AB Identifier: NCT01690689     History of Changes
Other Study ID Numbers: ALCR-120412-01
First Posted: September 24, 2012    Key Record Dates
Last Update Posted: February 24, 2015
Last Verified: February 2015

Additional relevant MeSH terms:
Cartilage Diseases
Musculoskeletal Diseases
Connective Tissue Diseases